Palo Alto, CA's Neurotrack launched its first product, the Imprint, a digital cognitive assessment test for the evaluation of patients who may be at risk for cognitive decline. The goal is to advance research and treatment of cognitive diseases like Alzheimer's. In addition, the company reported $6.5 million in new funding, led by Khosla Ventures and supported by Social Capital, Founders Fund, AME Cloud Ventures and iSeed Ventures. The web-based test takes 5 minutes and utilizes eye-tracking technology to assess recognition memory and hippocampal impairment. Release